NCT03211052View on ClinicalTrials.gov

A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 18, 2013

Primary Completion Date

June 2, 2015

Study Completion Date

June 2, 2015

Conditions
Prostate Cancer
Interventions
DRUG

TAK-700 and LHRH agonist

TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy

PROCEDURE

prostatectomy

SURGICAL REMOVAL OF THE PROSTATE

Trial Locations (1)

Unknown

St Bartholomew's Hospital, London

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Centre of Experimental Medicine

OTHER

NCT03211052 - A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone | Biotech Hunter | Biotech Hunter